Literature DB >> 8947500

Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas.

H J Hansen1, G L Ong, H Diril, A Valdez, P A Roche, G L Griffiths, D M Goldenberg, M J Mattes.   

Abstract

The fate of antibody (Ab) LL1, which reacts with the invariant chain (Ii) subunit of the immature MHC class-II antigen (CD74) after binding to the surface of B-cell lymphomas was investigated. This Ab was internalized and catabolized very rapidly, much faster than other Abs that are considered to be rapidly internalized, such as CD19, CD22 and anti-(transferrin receptor). Such internalization did not depend on Ab cross-linking. The capacity of this uptake process was determined in long-term experiments by increasing the Ab concentration: in 1 day, approx. 8 x 10(5) Ab molecules per cell were catabolized. This analysis was facilitated by the use of radiolabels that are trapped within cells after catabolism of the Abs to which they were conjugated. If the Ab is a reliable marker for the Ii antigen, which is likely, we can conclude that Ii directed to the cell surface appears to be sufficient, indeed more than sufficient, to account for the cell content of mature class-II molecules.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947500      PMCID: PMC1217930          DOI: 10.1042/bj3200293

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.

Authors:  O W Press; A G Farr; K I Borroz; S K Anderson; P J Martin
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

2.  Cell surface expression of invariant gamma-chain of class II histocompatibility antigens in human skin.

Authors:  L Claesson-Welsh; A Scheynius; U Tjernlund; P A Peterson
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

3.  Intracellular transport of invariant chain-MHC class II complexes to the peptide-loading compartment.

Authors:  X Xu; W Song; H Cho; Y Qiu; S K Pierce
Journal:  J Immunol       Date:  1995-09-15       Impact factor: 5.422

Review 4.  The ways of endocytosis.

Authors:  B van Deurs; O W Petersen; S Olsnes; K Sandvig
Journal:  Int Rev Cytol       Date:  1989

5.  Temperature-induced variations in the surface topology of cultured lymphocytes are revealed by scanning electron microscopy.

Authors:  P S Lin; D F Wallach; S Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

Review 6.  Receptor-mediated endocytosis: concepts emerging from the LDL receptor system.

Authors:  J L Goldstein; M S Brown; R G Anderson; D W Russell; W J Schneider
Journal:  Annu Rev Cell Biol       Date:  1985

7.  Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma.

Authors:  E J Pawlak-Byczkowska; H J Hansen; A S Dion; D M Goldenberg
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

8.  Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.

Authors:  A L Epstein; R J Marder; J N Winter; E Stathopoulos; F M Chen; J W Parker; C R Taylor
Journal:  Cancer Res       Date:  1987-02-01       Impact factor: 12.701

9.  Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells.

Authors:  C R Hopkins; I S Trowbridge
Journal:  J Cell Biol       Date:  1983-08       Impact factor: 10.539

10.  Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics.

Authors:  W A Dunn; A L Hubbard
Journal:  J Cell Biol       Date:  1984-06       Impact factor: 10.539

View more
  26 in total

1.  Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.

Authors:  Cody P Coyne; Toni Jones; Andrzej Sygula; John Bailey; Lesya Pinchuk
Journal:  J Cancer Ther       Date:  2011-03

2.  Involvement of clathrin and AP-2 in the trafficking of MHC class II molecules to antigen-processing compartments.

Authors:  Peter J McCormick; José A Martina; Juan S Bonifacino
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

3.  Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

Authors:  M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

Review 4.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

5.  Major histocompatibility complex class II-peptide complexes internalize using a clathrin- and dynamin-independent endocytosis pathway.

Authors:  Even Walseng; Oddmund Bakke; Paul A Roche
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

6.  Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.

Authors:  G L Ong; D M Goldenberg; H J Hansen; M J Mattes
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 7.  Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Authors:  Cédric Rossi; Marie-Lorraine Chrétien; René-Olivier Casasnovas
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

8.  Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549).

Authors:  C P Coyne; Lakshmi Narayanan
Journal:  J Pharm Drug Deliv Res       Date:  2015-03-20

9.  Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma.

Authors:  C P Coyne; Toni Jones; Ryan Bear
Journal:  J Clin Exp Oncol       Date:  2013

10.  Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.

Authors:  Yicheng Mao; Georgia Triantafillou; Erin Hertlein; William Towns; Matthew Stefanovski; Xiaokui Mo; David Jarjoura; Mitch Phelps; Guido Marcucci; Ly James Lee; David M Goldenberg; Robert J Lee; John C Byrd; Natarajan Muthusamy
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.